| Comparison | Outcome | Conclusion | Study Design and Sample Sizea | Factors That Affect the Strength of evidenceb | Overall Evidence Strength (Direction of Effect) |
|---|---|---|---|---|---|
| Fluoxetine (class: SSRI) vs. Clomipramine (class: TCA) | Primary anxiety, child report | SMD: −1.01; 95% CI: −2.02 to −0.09; I2=N/A | 1 RCT (19 Patients)54 | Severe imprecision (wide CIs and small sample size) | Low (reduced anxiety) |
| Remission | RR: 1.20; 95% CI: 0.69 to 2.09; I2=N/A | 1 RCT (19 Patients)54 | Severe imprecision (wide CIs and small sample size) | Low (no difference) | |
| Venlafaxine (class: SNRI) vs. Atomoxetine (class: SNRI) | Primary anxiety, child report | SMD: −0.12; 95% CI: −0.43 to 0.20; I2=N/A | 1 RCT (154 Patients)62 | Severe imprecision (wide CIs and small sample size) | Low (no difference) |
| Primary anxiety, parent report | SMD: −0.08; 95% CI: −0.39 to 0.24; I2=N/A | 1 RCT (154 Patients)62 | Severe imprecision (wide CIs and small sample size) | Low (no difference) | |
| Primary anxiety, clinician report | SMD: 0.25; 95% CI: −0.07 to 0.57 I2=N/A | 1 RCT (154 Patients)62 | Severe imprecision (wide CIs and small sample size) | Low (no difference) |
CI: confidence interval, N/A: not applicable, RCT: randomized control trial, RR: relative risk, SMD: standardized mean difference, SNRI: serotonin–norepinephrine reuptake inhibitor, SSRI: selective serotonin reuptake inhibitor, TCA: tricyclic antidepressants.
The sample size includes the number of patients from each comparison.
Only SOE domains that led to rating down SOE are reported in this column. Domains that are not reported were satisfactory.
From: Results
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.